DNTH Dianthus Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DNTH

Price (delayed)

$84.1

Market cap

$4.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.22

Enterprise value

$3.97B

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 97
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 28

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused ...

Highlights
DNTH's equity has soared by 143% QoQ
Dianthus Therapeutics's quick ratio has surged by 121% QoQ and by 86% YoY
The revenue has plunged by 80% YoY and by 34% from the previous quarter
The gross profit has dropped by 80% year-on-year and by 34% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.magentatx.com/
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of DNTH

DNTH stock price

How has the Dianthus Therapeutics stock price performed over time
Intraday
-1.02%
1 week
-7.44%
1 month
-5.87%
1 year
368.26%
YTD
104.08%
QTD
0.21%

Financial performance

How have Dianthus Therapeutics's revenue and profit performed over time
Revenue
$1.34M
Gross profit
$1.34M
Operating income
-$191.29M
Net income
-$173.66M
Gross margin
100%
Net margin
-12,998.5%
The revenue has plunged by 80% YoY and by 34% from the previous quarter
The gross profit has dropped by 80% year-on-year and by 34% since the previous quarter
Dianthus Therapeutics's net income has shrunk by 72% YoY and by 7% QoQ
The company's operating margin has shrunk by 64% QoQ

Price vs fundamentals

How does DNTH's price correlate with its fundamentals

Growth

What is Dianthus Therapeutics's growth rate over time

Valuation

What is Dianthus Therapeutics stock price valuation
DNTH P/E details
P/E
N/A
P/B
3.11
P/S
3,023.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,972.4
The EPS fell by 46% YoY
DNTH's equity has soared by 143% QoQ
The stock's price to book (P/B) is 85% more than its 5-year quarterly average of 1.7 and 17% more than its last 4 quarters average of 2.7
DNTH's P/S is 176% above its last 4 quarters average of 1104.9
The revenue has plunged by 80% YoY and by 34% from the previous quarter

Efficiency

How efficient is Dianthus Therapeutics business performance
The ROS has shrunk by 63% QoQ
The ROE has increased by 30% QoQ and by 7% YoY
DNTH's return on assets is up by 29% since the previous quarter and by 7% year-on-year
DNTH's return on invested capital is up by 8% since the previous quarter and by 5% year-on-year

Dividends

What is DNTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNTH.

Financial health

How did Dianthus Therapeutics financials performed over time
DNTH's total assets has soared by 135% QoQ
The company's total liabilities has surged by 128% YoY and by 21% QoQ
DNTH's debt is 100% smaller than its equity
DNTH's equity has soared by 143% QoQ
DNTH's debt is down by 2.3% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.